Home About Cancer News Contact Cancer News
Home About Cancer News Contact Cancer News
Twitter

Posts Tagged ‘asco’

« Older Entries

ASCO-GU Meeting Highlights

By on Wednesday, February 20th, 2013 | No Comments

The 2013 Genitourinary Cancers Symposium was more about expansion of knowledge than major practice changers. In an interview with The Oncology Report, Dr. Nicholas Vogelzang touches upon this year’s major studies on GU cancers and predicts what’s in the store for the coming year. For more coverage of ASCO-GU, visit www.oncologyreport.com.

Read More...

Surveillance May Be Best For Small Kidney Tumors

By on Wednesday, February 13th, 2013 | No Comments

Surveillance, or the watch and wait approach, may be the best option for older patients with small kidney tumors. The finding came from a large retrospective study which showed that surveillance is a safe alternative to surgery. The research will be presented at the American Society of Clinical Oncology (ASCO) conference on Saturday…

Read More...

Surveillance May Be Best For Small Kidney Tumors

By on Wednesday, February 13th, 2013 | No Comments

Surveillance, or the watch and wait approach, may be the best option for older patients with small kidney tumors. The finding came from a large retrospective study which showed that surveillance is a safe alternative to surgery. The research will be presented at the American Society of Clinical Oncology (ASCO) conference on Saturday…

Read More...

ASCO 2012: Radiotherapy for Locally Advanced Prostate Cancer

By on Sunday, August 12th, 2012 | No Comments

Dr. Malcolm Mason of Cardiff University in Wales discusses his report that adding radiotherapy to androgen deprivation therapy for locally advanced prostate cancer produced a durable survival benefit compared with hormone therapy alone. Findings come from the final 10-year analysis of a phase III intergroup trial carried out by the UK Medical Research Council, the National Cancer Institute of Canada, and the Southwest Oncology Group.

Read More...

PSA Prostate Cancer Screening For Men With Long Life Expectancies

By on Sunday, July 22nd, 2012 | No Comments

Doctors should discuss with their patients fully the risks and benefits of PSA prostate cancer screening if the patient has a life expectance of more than ten years, an ASCO (American Society of Clinical Oncology) Panel advised today in a new evidence-based PCO (provisional clinical opinion)…

Read More...

Dabrafenib And Trametinib For Metastatic Melanoma Meet Primary Endpoints In Phase III Studies

By on Tuesday, June 5th, 2012 | No Comments

Phase III human trials of single agent therapy using dabrafenib and trametinib for patients with BRAF V600 mutation positive metastatic melanoma met their primary endpoints, GSK (GlaxoSmithKline) reported at the Annual Meeting of ASCo (American Society of Clinical Oncology), Chicago, Illinois, today. The trial results were also published today in NEJM (New England Journal of Medicine)…

Read More...

ASCO: New Treatment for HER2-Positive Advanced Breast Cancer?

By on Sunday, June 3rd, 2012 | No Comments

“A phase III randomized study of the investigational agent trastuzumab emtansine (T-DM1) versus standard therapy using capecitabine (Xeloda) and lapatinib (Tykerb) found significant and clinically meaningful improvement in progression-free survival (PFS) for T-DM1 in women with HER2-positive locally advanced or metastatic breast cancer previously treated with a taxane and trastuzumab,” according to a news release. Lead author, Dr. Kimberly Blackwell, discusses the findings. For more, visit www.oncologypractice.com.

Read More...

Fox Chase analysis finds more cutting-edge cancer research supported by industry

By on Saturday, May 19th, 2012 | No Comments

Nearly half of the research presented at ASCO’s annual meeting last year came from researchers with ties to companies, and the amount appears to be increasing every year, according to new findings from Fox Chase Cancer Center. The new findings will be presented this year at the 2012 American Society of Clinical Oncology Annual Meeting on Monday, June 4.

Read More...

Sloan-Kettering study finds testing for mutations identified in squamous cell lung cancer tumors helps personalize treatment

By on Friday, May 18th, 2012 | No Comments

Screening lung cancer tumor samples for cancer-causing, or “driver,” genetic mutations can help physicians tailor patients’ treatments to target those specific mutations… Now, researchers from Memorial Sloan-Kettering Cancer Center have begun testing for three new genetic targets and found that together they occur in approximately 50 percent of patients with squamous cell carcinomas of the lung, which affects 40,000 Americans each year. Initial findings of the research will be presented on June 4 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.

Read More...

A Conversation with Dr. Thomas Smith on the Growing Role of Palliative Care for Patients with Cancer

By on Wednesday, March 21st, 2012 | No Comments

The American Society of Clinical Oncology (ASCO) recently released a Provisional Clinical Opinion (PCO) recommending that palliative care be integrated with cancer treatment early in the course of illness for any patient who has metastatic cancer or is greatly burdened by symptoms.

Read More...
« Older Entries